Teva Agilect "approvable" again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva Parkinson's disease treatment Agilect (rasagiline) receives a second "approvable" letter Aug. 4. "There remain a number of issues that Teva believed it had resolved with its submissions, but [where] FDA continues to have concerns," the sponsor states Aug. 5. The firm plans to meet with the agency "promptly" to address the remaining concerns. Teva responded to a July 2004 approvable letter last November, but the review was extended by three months due to a technical error with the NDA...
You may also be interested in...
FDA Turns To Epidemiological Data To Resolve Azilect Melanoma Questions
FDA used an epidemiological approach to resolve concerns regarding a potentially higher risk of melanoma with Teva’s Parkinson’s disease therapy Azilect, review documents show.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.